



Contact:
CCG Elite Investor Relations
Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com

For Immediate Release

China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results

Shanghai, China – August 9, 2007 – China-Biotics, Inc. (OTC BB: CHBT), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will conduct a conference call at 10:00 a.m. Eastern Time on Monday, August 13, 2007, to discuss the Company's financial results for the first quarter, ended June 30, of its 2008 fiscal year.

Hosting the call will be Jinan Song, Chairman and Chief Executive Officer, Raymond Li, Chief Financial Officer, and Henry Tai, Vice President of Corporate Development.

To participate in the event by telephone, please dial (800) 374-0113 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 12771683. International callers should dial (706) 758-9607.

A digital replay of the call will be available on Monday, August 13 at approximately 12:00 pm Eastern Time through Monday, August 27 at midnight Eastern Time. To listen to the replay dial (800) 642-1687 and enter the conference ID number 12771683. International callers should dial (706) 645-9291 and enter the same conference ID number.

The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company's Web site, <http://www.chn-biotics.com>.

To monitor the live webcast, please go to this web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China-Biotics' Web site, at <http://www.chn-biotics.com/>, for 90 days.

About China-Biotics, Inc.

China-Biotics, Inc. (“China-Biotics”, “the Company”), a leading manufacturer of biotechnology products and supplements, engages in research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the “Shining” brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand stores in major cities in China during the next two years. The Company’s flagship product, “Shining Essence,” was approved by the Chinese Ministry of Health for production and to market as a health product in August 2000, and has been a profit driver since its launch in Shanghai in April 2001. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company’s ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###